CUE BIOPHARMA, INC.
Last · NasdaqCM$18.60-0.97 (-4.96%)close · yahoo · 16h ago
Market cap$135.12M7.3M sh
P/E · TTM-0.6fwd -38.8 · eps -29.59 · loss
Beta2.63vs S&P 500
Div yield0.00%annual · TTM
52w range
$4.98$45.50
Volume245.0Ksession
| Revenue | $37.7M |
|---|---|
| Operating income | $-93.0M |
| Net income | $-158.2M |
| Free cash flow | $-40.1M |
| Operating margin | -247.1% |
| Net margin | -420.2% |
| Return on equity | -598.7% |
| Period | TTM 2026-06-30 |
Loading chart…
OpenFilings analyst
Our analyst
From latest 10-K · 2026-03-16
- Operating Cf Burn
- Net Margin Sharply Negative
- Cash Conversion Weak
- Cash Runway Low
- Sbc Revenue Elevated
- Accumulated Deficit High
- Rd Intensity High
Red flags
- Operating Cf Burn — Negative operating cash flow
- Net Margin Sharply Negative — Net margin -96.9%
- Cash Conversion Weak — Cash conversion (CFO/Rev) -79.0%
- Cash Runway Low — Cash runway ~1.3 years
- Sbc Revenue Elevated — SBC/Revenue 17.3%
- Accumulated Deficit High — Accumulated deficit / equity 1394%
- Rd Intensity High — R&D/Revenue 137.4%
Press & signals
- GlobeNewswire
Cue Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights
- GlobeNewswire
Cue Biopharma Announces Appointment of James M. Ahlers as Chief Financial Officer and CUE-221 Investigational New Drug Submission
- GlobeNewswire
Cue Biopharma Appoints Dominic Borie, M.D., Ph.D., as Chief Medical Officer and Head of Research & Development
The rest of this company's wire — with summaries and source links — is part of Pro.
See plans